Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 45

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 45
---
 to maintain a solid investment grade credit rating and to return cash to shareholders. In addition to these improvements, we also seek to improve operational efficiency across our organization through implementing transformational initiatives. On May 9, 2024, we announced a multi-year, enterprise-wide efficiency program aimed at promoting business growth and improving our profitability. This program includes increasing the agility and simplicity of our business organization, investing in digital, data and technology to enhance productivity and efficiency across the organization and implementing cost reductions and process improvements in supply chain and vendor management.

Table of Contents

The following is a summary of our principal products by business area.

In GI, our principal products include:

• ENTYVIO(vedolizumab), a treatment for moderate to severe ulcerative colitis and Crohn’s disease. Sales ofENTYVIO have grown strongly since its launch in the U. S. and Europe in 2014 and it was our top selling product in the fiscal year ended March 31, 2025. ENTYVIO is now approved in more than 70 countries worldwide with a subcutaneously administered formulation approved in the U. S., Europe and Japan. We strive to maximize its potential by seeking approval in additional countries, examining use in further indications. In the fisc al year ended March 31, 2025, our revenue from ENTYVIO was JPY 914.1 billion.

• EOHILIA(budesonide oral suspension), a therapy for eosinophilic esophagitis (EoE). EOHILIA is a corticosteroid, and the first and only FDA-approved oral therapy indicated for 12 weeks of treatment in patients 11 years and older with EoE. EOHILIA was approved by the U. S. FDA in February of 2024 and subsequently launched. In the fiscal year ended March 31, 2025, our revenue from EOHILIA was JPY 5.5 billion.

•TAKECAB/VOCINTI(vonoprazan fumarate), a treatment for acid-related diseases. TAKECAB was launched in Japan in 2015 and has achieved significant growth driven by its efficacy in reflux esophagitis and the prevention of recurrence of gastric and duodenal ulcers during low-dose aspirin administration. TAKECAB(Chinese brand name: VOCINTI) was approved for reflux esophagitis in 2019 in China. In the fiscal year ended March